

Group I. Claims 1-5, 18, 24 and 30, drawn to compounds of formula I and use, classified in class 514, subclass 217.

Group II. Claims 6-8, 19, 25 and 31, drawn to compounds of formula II and use, classified in class 514, subclass 367.

Group III. Claims 9-12, 20, 26 and 32, drawn to compounds of formula III and use, classified in class 514, subclass 231.5.


Group IV. Claims 13, 21, 27 and 33, drawn to compounds of formula IIIb and use, classified in class 514514, subclass 183.

Group V. Claims 14, 15, 22, 28 and 34, drawn to compounds of formula IV and use, classified in class 514, subclass 417.

Group VI. Claims 16-18, 23, 29 and 35, drawn to compounds of formula V and use, classified in class 514, subclass 226.5.

In response to the Restriction Requirement, Applicants hereby elect Group II, drawn to compounds of formula II, with traverse. Claims readable thereon include claims 6-8, 19, 25, 31 and newly added claims 36-41. No new matter has been added with the newly added claims, as they find support in Figures 2A and 2B as filed.

In response to the election of species requirement, Applicants elect the following species:



Although the foregoing species was disclaimed in claim 6, the composition claim 19 and the method claims 25 and 31 encompass the elected species.

Applicants assert that the restriction requirement is improper. Under MPEP § 803.01, there are two criteria for a proper requirement for restriction between patentably distinct inventions:


- (A) the inventions must be independent or distinct as claimed; and
- (B) there must be a serious burden on the examiner if restriction is required.

Applicants maintain that there is no serious burden on the Examiner to search claims 1-41 in their entirety.

CONCLUSION

In view of the foregoing, Applicants respectfully request early examination on the merits. If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 925-472-5000.

Respectfully submitted,



Joseph R. Snyder
Reg. No. 39,381

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 925-472-5000
Fax: 415-576-0300
JS:sea
WC 9055099 v1


1

VERSION WITH MARKINGS TO SHOW CHANGES MADE

2

3 36. (New) The pharmaceutical composition of claim 19, wherein said
4 compound is selected from the group consisting of the compounds set forth in Figures
5 2A and 2B.

1 37. (New) The pharmaceutical composition of claim 36, wherein said
2 compound is




3

1 38. (New) The method of claim 25, wherein said compound is selected
2 from the group consisting of the compounds set forth in Figures 2A and 2B.

1

39. (New) The method of claim 38, wherein said compound is



2

1 40. (New) The method of claim 31, wherein said compound is selected
2 from the group consisting of the compounds set forth in Figures 2A and 2B.

1

41. (New) The method of claim 40, wherein said compound is

